FDA say no to alemtuzumab

Has the FDA got it right regarding alemtuzumab? #MSBlog #MSResearch

"For those of you who may missed this Genzyme press release, from the 30th December, concerning the FDA decision regarding alemtuzumab. The bottom line is MSers in Europe will have access to alemtuzumab and MSers in the US will not; unless they can afford to travel to Europe or Canada for treatment and pay for it privately."


Labels: , ,